REQUEST A DEMO
Total
USD $0.00
Search more companies

OBI Pharma, Inc. (台湾浩鼎生技股份有限公司) (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing | Research and Development in Biotechnology (except Nanobiotechnology)
Full name: OBI Pharma, Inc. Profile Updated: May 28, 2026
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English & Chinese Download a sample report

OBI Pharma, Inc. (台湾浩鼎生技股份有限公司) is an enterprise based in Taiwan, China. Its main office is in Taipei City. It operates in the Pharmaceutical and Medicine Manufacturing sector. The company was established on April 29, 2002. 101 - 500 (2025) employees currently work for OBI Pharma, Inc. (台湾浩鼎生技股份有限公司). The company’s latest financial report indicates a net sales revenue drop of 23.41% in Q2C2026. Its’ total assets recorded a negative growth of 37.78%. The net profit margin of OBI Pharma, Inc. (台湾浩鼎生技股份有限公司) increased by 901.45% in 2026.

Headquarters
6F., No. 508, Sec. 7, Zhongxiao E. Rd Nangang Dist
Taipei City; Taipei City;

Contact Details: Purchase the OBI Pharma, Inc. (台湾浩鼎生技股份有限公司) report to view the information.

Website: http://www.obipharma.com

Basic Information
Total Employees:
Purchase the OBI Pharma, Inc. (台湾浩鼎生技股份有限公司) report to view the information.
Outstanding Shares:
Purchase the OBI Pharma, Inc. (台湾浩鼎生技股份有限公司) report to view the information.
Financial Auditors:
Purchase the OBI Pharma, Inc. (台湾浩鼎生技股份有限公司) report to view the information.
Incorporation Date:
April 29, 2002
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Vice President
Purchase this report to view the information.
General Manager
Ownership Details
Purchase this report to view the information.
9.79%
Purchase this report to view the information.
7.22%
Purchase this report to view the information.
4.88%
Purchase this report to view the information.
4.38%
Purchase this report to view the information.
2.93%
Subsidiaries
Obi Pharma Australiapty.Ltd. (Australia)
100%
Obi Pharma Usa Inc. (United States)
100%
潤雅生技股份有限公司
70.7%
Company Performance
Financial values in the chart are available after OBI Pharma, Inc. (台湾浩鼎生技股份有限公司) report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Net sales revenue
-23.41%▼
Total Operating Revenue
-58.71%▼
Operating Profit
39.69%▲
EBITDA
42.4%▲
Net Profit/Loss for the Period
38.4%▲
Total Assets
-37.78%▼
Total Equity
-38.41%▼
Operating Profit Margin
990.8%▲
Net Profit Margin
901.45%▲
Return on Equity (ROE)
-0.01%▼
Debt / Equity
5.36%▲
Quick Ratio
-2.84%▼
Cash Ratio
-1.86%▼

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?